ArticleChemical reviews2026
Triarylborane-Catalyzed Homogeneous Molecular Transformations Using Organic Reductants.
Article in Chemical reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Triarylboranes have emerged as powerful main-group catalysts for the reduction of organic molecules using a variety of reductants, including molecular hydrogen (H2), hydrosilanes, Hantzsch esters, and ammonia borane. This development has been largely enabled by the extensive structural diversification of triarylboranes, which allows for systematic tuning of the Lewis acidity and steric environment at the boron center. Since the seminal review of this area more than a decade ago, the field has undergone remarkable growth, prompting this comprehensive account covering three key directions: (1) triarylboranes that, unlike conventional B(C6F5)3, remain catalytically active in the presence of Lewis bases such as H2O, CO2, and CO, enabling the use of pure or crude H2; (2) diverse organic reductants, including ammonia borane, Hantzsch esters, cyclohexadienes, and other hydride donors; and (3) mechanistic insights into reductant activation and stereocontrol. Covering advances from 2016 to 2025, this review discusses innovations in borane design, substrate scope, functional-group tolerance, and mechanism across each reductant class. By unifying these related yet independent developments, it aims to provide synthetic chemists and theoreticians with timely insights into triarylborane-catalyzed homogeneous reductions, highlighting main-group catalysts as sustainable, practical alternatives to precious-transition-metal systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.